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OBJECTIVE – Beta-blockers remain important for secondary prevention after
myocardial infarction (MI). Despite clinical guideline recommendations, the potential for
poor glycemic control and masking warning signs of hypoglycemia limit their utilization
in type 2 diabetes. This study evaluated factors predicting post-MI beta-blocker initiation
among type 2 diabetic patients.
RESEARCH DESIGN AND METHODS – A retrospective cohort of employed,
commercially insured individuals was developed using de-identified enrollment files,
medical claims, and pharmacy claims from 2007-2009 in the U.S. Inclusion criteria: (1)
type 2 diabetes, (2) ≥18 years old, (3) continuous eligibility, (4) MI. Exclusion criteria:
(1) females prescribed metformin exclusively without diabetes diagnosis, (2) <6 months
eligibility pre-MI, (3) MI before diabetes identified, (4) pre-MI beta-blocker, (5) receipt
of sotalol post-MI, (6) no prescription claims, (7) <30 days between discharge and study
end. Multivariable logistic regression with manual backward elimination was used to
evaluate predictors of beta-blocker initiation.
RESULTS – Of 341 type 2 diabetic patients, only 167 (49.0%) initiated beta-blockers
within 30 days of discharge. Patients on a calcium channel blocker (ORadj: 2.63) and
patients taking 1 to 5 medications (ORadj: 3.59) were more likely to initiate beta-blockers
post-MI. Patients with heart failure (ORadj: 0.45) or an arrhythmia (ORadj: 0.44) were less
likely to initiate beta-blockers as well as patients with renal failure who are not taking a
diuretic (ORadj: 0.17).
CONCLUSIONS – Although these results might not apply to older populations, they
support the need for further investigation to determine whether more patients with type 2
diabetes could benefit from beta-blocker treatment post-MI.
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Existing evidence on the effect of beta-blockers in decreasing myocardial
ischemia, re-infarction, and the frequency of complex ventricular dysrhythmias as well as
increasing long-term survival supports the key role these drugs play in secondary
prevention after myocardial infarction (MI).1 In fact, current guidelines for cardiovascular
secondary prevention recommend initiation of oral beta-blockers within 24 hours of a
MI;1,2 furthermore, in patients with an ST-elevation MI (STEMI), this therapy is
recommended for 3 years post-MI.2
However, beta-blockers have a history of relative contraindication in diabetic
patients based on their potential to mask the warning signs of hypoglycemia3-7 and
negatively impact glycemic control through beta-3 adrenergic receptor blockade on
adipocytes.5,7-10 These effects are potentially more likely for nonselective beta-blockers.
This brings about somewhat of a paradox. Patients with type 2 diabetes typically have
worse cardiovascular outcomes after MI,7 suggesting they may have more to gain from
beta-blocker therapy for secondary prevention. However, cardiovascular outcomes in
diabetic patients are often improved through tight glycemic control,9 which may be
worsened by beta-blocker therapy. There is also evidence that beta-blockers restore
sympathovagal balance in diabetic patients with neuropathy and may also decrease the
use of fatty acids in the myocardium, thereby decreasing oxygen demand.4
Although current guidelines from the American Diabetes Association (ADA)
recommend the use of beta-blockers in type 2 diabetic patients after a MI,11,12 few studies
have formally evaluated the use of beta-blockers in this population.3,13-17 One
observational study from Canada in the 1990s found that approximately 43% of type 2
diabetic patients without previous exposure received beta-blockers after a MI.3 Other
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studies have also found low rates of beta-blocker utilization among patients with type 2
diabetes when compared to patients without diabetes.14,15 Patients taking other
medications with an elevated risk of hypoglycemia (e.g. insulin and sulfonylureas) may
be even less likely to be prescribed beta-blockers after a MI.15
Few studies have evaluated beta-blocker utilization among patients with type 2
diabetes after a MI in the United States.15,16 While clinical guidelines are relatively
straightforward in this population, it is important to understand why real-world practice
deviates from these recommendations so often. The purpose of this study was to
determine the clinical and socioeconomic characteristics of type 2 diabetic patients that
predict initiation of a beta-blocker to identify which patients are more or less likely to
receive beta-blockers after MI. These predictors would provide useful knowledge of
potential confounders to include in the evaluation of outcomes related to beta-blocker
therapy. Also, clinicians and policymakers could potentially utilize this information to
help develop interventions to improve the rate beta-blocker initiation in a post-MI setting
if the treatment benefits are indeed significant for type 2 diabetic patients.

Research Design and Methods
Settings and databases
This study was conducted using secondary claims data from a population of
employed, commercially insured individuals with dependents from January 2007 through
December 2009. From this data, a retrospective cohort was developed to evaluate
predictors of new users of beta-blockers among type 2 diabetic patients after discharge
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from hospitalization due to MI. The de-identified dataset included information on patient
enrollment files, medical claims, and pharmacy claims.
The following inclusion criteria were used to identify patients with type 2 diabetes
post-MI: (1) diabetes identified through the first instance of ICD-9 codes for type 2
diabetes in medical claims or prescription claims for oral diabetes medications identified
through National Drug Codes (NDCs), (2) patients who were at least 18 years of age, (3)
continuous eligibility through the entire study period, and (4) MI identified through ICD9 codes (all codes of the form 410.X1 as the primary or secondary diagnosis only). If a
patient had multiple MIs during the study period, the first episode was considered the
index MI.
Exclusion criteria included the following: (1) females with no type 2 diabetes
diagnosis and receiving metformin as the exclusive oral diabetes medication, (2) less than
6 months of eligibility prior to first MI identified, (3) MI identified in claims before
diabetes was identified, (4) receipt of a beta-blocker in prescription claims in the 6
months prior to index MI, (5) receipt of sotalol as the first beta-blocker after MI, (6) no
prescription claims for the duration of the study, and (7) less than 30 days between index
discharge date and the end of the study. Female patients having no ICD-9 diagnosis for
diabetes and receiving only metformin were excluded to prevent misclassification of
patients with polycystic ovary syndrome as patients with diabetes. Patients receiving the
beta-blocker sotalol after MI were excluded as this medication is indicated for the
treatment of arrhythmias and is not indicated for secondary prevention of MI. See Figure
1 for a flowchart depicting study design and cohort selection.
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Predictors of beta-blocker initiation
Predictors of beta-blocker receipt were demographic and clinical characteristics as
well as measures of health care utilization. Demographic characteristics investigated
include age, sex, race, and proxy measures of socioeconomic status including education,
annual household income, and geographic region of residence. Clinical characteristics
included both comorbidities and other medications the patient was taking prior to MI.
Comorbidities were identified through the Elixhauser Comorbidity algorithm for the 6
months preceding MI18 (see Table 1 for a full list of comorbidities). Patients taking
insulin or insulin secretagogues (sulfonylureas and meglitinides) 90 days before index MI
were identified, as these patients are likely at a higher risk of hypoglycemia.
Additionally, patients taking any diabetes medication including insulin 90 days prior to
index MI were identified. Patients taking other medications that could lower blood
pressure were identified (see Table 1 for a full list of antihypertensive medication
classes). Statin users were also identified to see if patients already taking post-MI
recommended therapy were more likely to initiate beta-blockers.
Number of prescription medications filled in the 90 days before index MI was
used as a measure of health care utilization. The American Hospital Formulary Service
(AHFS) Drug Information code was used to identify unique classes of medication. NDCs
are linked to the AHFS codes to group unique drug products into drug classes.
Prescription claims with no AHFS code or that were coded as unknown were not
included in this count. Additionally, AHFS codes for medical products such as glucagon
emergency kits (682212), lancets and other insulin testing sharps (940000), and insulin
testing strips (362600) were not included in this count. All other unique AHFS codes
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were included in the number of prescription medications received in the 90 days before
index MI. Additionally, patients with a prescription fill for insulin testing strips 90 days
prior to MI were identified as patients who were currently testing their blood glucose.
Some clinicians have stated that diabetic patients who self-monitor blood glucose may be
better candidates for beta-blocker therapy after MI.7
Outcome
The primary outcome of interest was receipt of a beta-blocker as identified in
prescription claims within 30 days after hospital discharge. Beta-blockers were identified
using the AHFS code 242400; this includes all beta-blockers and all combination
medications with a beta-blocker in it. Patients who initiated beta-blockers within 30 days
of hospital discharge were considered new users of beta-blockers. All other patients were
identified as non-users. As stated previously, patients with previous beta-blocker
exposure greater than 6 months before index MI were kept in the cohort to prevent
selection bias; these patients were defined as new users versus non-users based solely on
having a prescription claim for a beta-blocker after index hospital discharge.
Statistical analysis
Baseline demographic, clinical, and health care utilization characteristics were
summarized for the entire population. Age was the only continuous variable and was
evaluated using mean ± standard deviation (SD). Categorical variables were summarized
using number (%) of patients with the given characteristic.
Unadjusted bivariable statistics were used to compare new users to non-users of
beta-blockers after MI among type 2 diabetic patients. A 2-sample t-test was used to
compare the age of new users and non-users. For all other variables, a chi-square test (or
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Fisher’s exact test where appropriate) was used to compare new users to non-users (α =
0.05 for all bivariable analyses).
Descriptive statistics for the first prescription fill of beta-blockers among new
users were also summarized including copay, beta-blocker agent used, and
pharmacologic properties of beta-blocker used. Pharmacologic properties include
cardioselective versus nonselective beta-blockers, beta-blockers with intrinsic
sympathomimetic activity (ISA), and beta-blockers with auxiliary mechanisms of action
such as alpha-antagonism and nitric oxide-dependent vasodilation.
A multivariable logistic regression model was utilized to predict new users and
non-users of beta-blockers among type 2 diabetic patients after MI. The one patient
(0.3%) with a missing value for race was added to the “Other” category, and missing
values for education (N = 8; 2.3%) and income (N = 21; 6.2%) were replaced with the
mode to allow patient inclusion in the regression analysis. Variables to be included in the
initial regression model as predictors of receipt or non-receipt of beta-blockers were
identified based on a combination of statistical significance in the bivariable analyses,
identification in the literature, and clinical judgment (see Table 3 for a list of variables
included in the initial model). Manual backward elimination was used to identify the best
model using the Akaike information criterion (AIC) for model selection; variables with
the highest P value were removed until the model with the minimum AIC value was
identified. After model reduction, variables remaining in the model were evaluated for
interactions using a similar manual backward elimination approach. Interactions to be
included in the final model reduction were selected based on identification in the
literature and clinical judgment. Adjusted odds ratios (ORadj) with 95% confidence
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intervals (CI) were reported for all variables included in the final model. Internal
validation of the final predictive model was completed using leave-one-out crossvalidation. All statistical analyses were completed using SAS® software (Version 9.4 of
the SAS System for Windows, Copyright © 2002-2012, SAS Institute, Cary, NC).

Results
Description of study cohort
Out of 396,619 patients who were identified as having type 2 diabetes, 743
patients (about 1.9 out of 1,000 patients) had a MI during the 2007-2009 study period
(Figure 1). Of these patients, 334 (45.0%) had a prescription claim for a beta-blocker
within the 6 months before their index MI. After excluding patients with no prescription
claims for the entire study period and patients discharged within 30 days of study end,
341 patients were included in the study cohort. Of these patients, 48 (14.1%) had
previous exposure to a beta-blocker outside of the 6-month pre-MI window. When these
patients were compared to the rest of the cohort, there was no significant difference in the
rate of beta-blocker initiation after hospital discharge (unadjusted OR: 0.86; P = 0.639).
The mean age of the cohort was 63.3 years (Table 1). Most patients were white
(76.2%) and 58.4% of patients were male. Only 64 patients (19.2% of those reporting)
had received a college degree including an associate degree or higher. Self-reported
annual household income was categorized based on the distribution of values in the
cohort. Among patients who reported income, about half (54.1%) reported annual
household incomes in the $30,000 to $74,999 range while 17.5% and 28.4% of patients
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belonged to the lower and higher income brackets, respectively. A large proportion of
patients (56.0%) resided in the South based on U.S. Census geographic regions.
The most common comorbidities identified among the cohort prior to the index
MI (Table 1) were hypertension (66.9%), cardiac arrhythmia (21.7%), chronic pulmonary
disease (21.4%), congestive heart failure (16.1%), and peripheral vascular disorder
(15.0%). Polypharmacy was identified as having prescription claims for 6 or more AHFS
classes of medications within 90 days prior to index MI; 156 (45.8%) of patients fell into
this category while 62 (18.2%) and 123 (36.1%) patients had either no medications or 1
to 5 medications prior to MI, respectively. Only 165 (48.4%) had a prescription claim for
a diabetes medication in the 90 days prior to index MI. Among these patients, 69 (20.2%)
had a claim for insulin and 63 (18.5%) had a claim for either a sulfonylurea or a
meglitinide. Only 67 (19.7%) of all cohort patients had an identified claim for blood
glucose testing strips. The most common antihypertensive medications were ACE
inhibitors and ARBs (111 patients; 32.6%) and diuretics (77 patients; 22.6%). Only 31
patients (9.1%) were on a calcium channel blocker. There were 130 patients (38.1%) who
received a statin in the 90 days prior to MI. Among the final cohort, 167 patients (49.0%)
were identified as new users of beta-blockers while 174 patients (51.0%) were identified
as non-users.
Bivariable analyses
New users (61.1 ± 11.1) were younger than non-users (65.3 ± 14.5; P = 0.003) of
beta-blockers post-MI (Table 2). Male patients were more likely to receive a beta-blocker
after MI with an unadjusted OR of 1.67 (P = 0.021). Among new users, 78.9% and 4.8%
of patients were white and black, respectively, compared to 73.6% and 10.9% in the non-
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users group (P = 0.115). In the unadjusted bivariable analyses, patients with congestive
heart failure (OR: 0.33; P < 0.001), cardiac arrhythmia (OR: 0.39; P = 0.001), chronic
pulmonary disease (OR: 0.58; P = 0.041), renal failure (OR: 0.35; P = 0.004), and fluid
and electrolyte disorder (OR: 0.32; P = 0.001) were less likely to receive a beta-blocker
within 30 days of MI hospital discharge. When comparing new users to non-users, there
was no difference among patients with hypothyroidism (11.4% and 17.2%, respectively;
P = 0.123). There was a significant difference when comparing number of medication
classes being utilized prior to MI between new users and non-users of beta-blockers (P <
0.001). Among new users, 53.3% of patients were taking a diabetes medication prior to
index MI compared to 43.7% among non-users (P = 0.076). Patients taking an ACE
inhibitor or ARB (OR: 1.68; P = 0.026), a calcium channel blocker (OR: 2.36; P =
0.028), or a diuretic (OR: 2.02; P = 0.008) were more likely to receive a beta-blocker
after hospital discharge as well.
Among the 167 new users in the cohort, the distribution of first beta-blockers
utilized follows: 75 patients (44.9%) received metoprolol tartrate, 33 (19.8%) received
metoprolol succinate, 51 (30.5%) received carvedilol, and 8 patients (4.8%) received
either atenolol, nebivolol, or propranolol. All of these beta-blockers were cardioselective
except carvedilol (which also has an ancillary alpha-1 antagonism mechanism of action)
and propranolol. None of these beta-blockers had intrinsic sympathomimetic activity
(ISA).
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Multivariable logistic regression model
All variables from Table 2 were considered for inclusion in the initial
multivariable logistic regression model. The comorbidities of pulmonary circulation
disorder, liver disease, and obesity were excluded from the initial model because so few
patients had these conditions. Additionally, obesity is often not well captured by ICD-9
codes. The antihypertensive classes of vasodilator and other antiadrenergics were
combined into one category for inclusion in the model. Due to issues of multicollinearity,
it was decided to include only one measure of socioeconomic status in the initial
regression model, either college degree or annual income. Whether education or income
was included in the initial model, the same final model resulted. The initial model that
included income was utilized to fit the model.
The initial multivariable regression model had an AIC of 445.559. After model
reduction, the AIC decreased to 421.235 and included the following variables: age, sex,
race, congestive heart failure, cardiac arrhythmia, renal failure, depression, fluid and
electrolyte disorder, number of medications, calcium channel blocker, and diuretic. Other
race compared to white (ORadj: 0.74; CI: 0.38–1.45) was not associated with receipt of a
beta-blocker after a MI. However, black patients (ORadj: 0.37; CI: 0.14–0.99) were less
likely to receive a beta-blocker compared to white patients; therefore, the race variable
was changed to indicate whether the patient was black for further model reductions.
Interactions to investigate in the regression model were based on clinical
knowledge and included (1) age with number of medications, (2) race with calcium
channel blocker use, (3) congestive heart failure with fluid and electrolyte disorder, (4)
congestive heart failure with diuretic use, (5) cardiac arrhythmia with calcium channel
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blocker use, (6) renal failure with diuretic use, and (7) depression with number of
medications. With the addition of these interaction terms, the AIC was 426.758. The final
reduced model had an AIC of 416.904.
The final reduced multivariable regression model including interaction terms can
be seen in Table 3. Patients taking 1 to 5 medications prior to index MI (ORadj: 3.59; CI:
1.74–7.38) were significantly more likely to receive a beta-blocker within 30 days posthospital discharge when compared to patients taking no medications; patients taking
calcium channel blockers before index MI were also more likely to receive a beta-blocker
after hospital discharge (ORadj: 2.63; CI: 1.05–6.60). Patients with congestive heart
failure (ORadj: 0.45; CI: 0.21–0.96) or a cardiac arrhythmia (ORadj: 0.44; CI: 0.23–0.86)
were less likely to initiate beta-blocker therapy post-MI. Among patients who were not
taking a diuretic prior to index MI, patients with renal failure were less likely to initiate
beta-blocker therapy as well (ORadj: 0.17; CI: 0.05–0.65); this association was not seen
among patients with renal failure who were taking a diuretic (ORadj: 1.42; CI: 0.35–5.86).
The c-statistic for the final fitted regression model was 0.767 (CI: 0.717–0.816). Using
the leave-one-out cross-validation method, the c-statistic was reported as 0.719 (CI:
0.665–0.773).
Four sensitivity analyses were run to determine if imputation of missing values
significantly impacted the final model. As education and income were the first variables
eliminated in their respective models, the first two sensitivity analyses were conducted by
excluding patients with missing values for education and income, respectively. In these
two models, all point estimates had less than 10% relative change except fluid and
electrolyte disorder and polypharmacy decreased 12.5% and 10.3%, respectively, in the
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education model and congestive heart failure increased 11.1% in the income model. Two
other sensitivity analyses were conducted by excluding the one patient with a missing
value for race and changing the value of race to black. In the first sensitivity analysis, all
point estimates had less than 10% relative change except renal failure among patients
taking diuretics decreased 12.7%. When the race for that single patient was changed to
black, no significant relative changes in point estimates occurred except a 13.6% increase
in the black variable. The c-statistic changed less than 1% in all four sensitivity analyses.

Conclusions
Despite recommendations from clinical guidelines, beta-blocker treatment
continues to be underutilized in type 2 diabetic patients in the setting of secondary MI
prevention. Only 49.0% of 341 patients in this study had a beta-blocker prescription
claim within 30 days after their hospital discharge; this is similar to rates of beta-blocker
treatment in this population previously reported.3 Even in this relatively young post-MI
population, age was an important factor in bivariable analyses and was included in the
final model. Age was trending towards significance in the final regression model,
signifying that power may not have been met. Similarly, the best-fit model had sex in it
although it was not significant; male patients may have been found to be more likely to
initiate beta-blocker therapy in this setting if the cohort had been larger. Race also
appeared to be a significant predictor of initiating beta-blocker therapy in this population
until interaction terms were added to the model; it is possible that power was not met due
to the low number of non-white patients in our cohort. Black patients with type 2 diabetes
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may be significantly less likely to initiate beta-blocker therapy after MI, and this
association should be further evaluated in a more diverse population.
The strongest predictor of initiating beta-blocker therapy was number of
medications filled within the 90 days prior to index MI; however, patients filling 6 or
more medications in this period were no more likely to initiate a beta-blocker than
patients taking no medications. It is not surprising that patients with a chronic condition
such as diabetes who were taking no medications previously would be less likely to
initiate a new preventative therapy. However, it is not clear why patients with no
medications had similar rates of initiation compared to patients with 6 or more
medications. Polypharmacy may be related to pill burden and patients not wanting to
initiate a new therapy; it could also be related to drug interactions and safety concerns
associated with the initiation of a beta-blocker. Patients taking a calcium channel blocker
prior to MI were also more likely to initiate beta-blocker therapy. This may be related to
patient behavior because the percent of patients taking other preventative therapies was
higher in the new users group for all medications except vasodilators in the bivariable
analyses.
Patients with a history of cardiac arrhythmia were less likely to initiate therapy.
This could be related to the antiarrhythmic effects of beta-blockers and the potential to
worsen this comorbidity with the addition of a beta-blocker if the patient was already
controlled on another antiarrhythmic medication. The use of diuretics may have served as
a proxy for the severity of renal failure in the interaction within our model as diuretics are
typically not recommended in patients with severe renal failure. While renal insufficiency
is an important consideration for many drug therapies, this finding is interesting given
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that most beta-blockers, including metoprolol and carvedilol, are not significantly
eliminated in the urine before hepatic metabolism. Among patients not taking diuretics
prior to index MI, renal failure patients were significantly less likely to initiate betablocker therapy. This association was not present when considering patients who were
taking a diuretic prior to index MI. It is interesting to note that although not always
statistically significant, new users had smaller percentages of patients among all
comorbidities except pulmonary circulation disorder and liver disease in the bivariable
analyses. This again seems to align with the healthy user phenomenon.
This study confirms previous findings that beta-blockers are underutilized among
patients with type 2 diabetes for secondary prevention of MI3,14,15 despite current
recommendations.1,2,11 Male patients have also been shown to be more likely than
females to receive beta-blockers among this population.3 To our knowledge, this is the
only observational study that has evaluated initiation of beta-blocker therapy in this
population while adjusting for other medication therapy, including number and classes of
medication. This is also the only study to investigate beta-blocker initiation in a type 2
diabetes post-MI population with a mean age less than 65.
Some limitations exist in our study. First, lab values were not available for a
majority of patients near the time of hospital discharge. This is a common limitation in
studies utilizing administrative claims data. Clinical decisions in diabetic patients rely
heavily on glycemic control and this information may have provided added predictive
value for our model. Secondly, our study could not account for prescriptions filled
outside of coverage. The trend of marketing out-of-pocket low-cost prescription
medications began in 2006 and included both metoprolol and carvedilol by the end of
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2007.19 This creates a potential for misclassification bias. However, among the 167 new
users of beta-blockers in our study, 7.8, 22.8, and 69.5% of patients had a co-pay of $0,
between $0 and $4, and more than $4, respectively, when standardized to a 30-day
supply. When these co-pay categories were stratified by income, 60.9, 65.5, and 79.2% of
patients were paying more than $4 for a 30-day supply of a beta-blocker in the low-,
middle-, and high-income categories, respectively. With such a high proportion of
patients paying more than $4 per 30-day supply for a beta-blocker, $4 prescriptions may
not have affected the behavior of patients with prescription insurance. In addition,
excluding patients with no prescription claims in the entire study period may keep some
of these patients out of the study population. Finally, we were not able to detect if
patients were non-users because they were not prescribed a beta-blocker or because they
chose not to fill a prescription they received after hospital discharge. Identifying whether
patients received beta-blocker treatment is more important than why they did or did not
receive the medication when evaluating outcomes related to this treatment; however, if
post-MI beta-blocker therapy in patients with type 2 diabetes is indeed beneficial,
identifying why patients are not receiving this therapy is an important step in solving the
issue of underutilization.
However, our study also possesses several strengths. Unlike previous research,
our study adjusted for the number and types of medications when evaluating initiation of
beta-blockers among this population. This is an important factor in better understanding
the behavior of both prescribers and patients. Also, cross-validation was conducted to
show the anticipated predictive power of our model if used with a different dataset in a
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similar population. Finally, the inclusion of patients with only continuous eligibility and
at least 6 months of data prior to index MI reduced the likelihood of bias.
The predictors identified in our final model set a strong foundation for future
investigations of the outcomes associated with the use of beta-blockers in this population.
If (1) the variables are available and reliable, and (2) the variables are related to the
outcome of interest, all variables in our final model should be considered for adjustment
in observational studies examining outcomes related to beta-blocker therapy in this
population. Our study also confirms the results from previous researchers that betablockers are underutilized in this population. The results from this study could help
clinicians and policymakers determine if more patients with type 2 diabetes should be
receiving beta-blocker therapy post-MI and could assist in developing interventions
targeted to patients less likely to receive this therapy.
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Figure 1 – Selection of study cohort
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Table 1 – Cohort characteristics
Patient characteristics
N = 341
Age (years)
63.3 ± 13.1
Sex
Male
199 (58.4)
Female
142 (41.6)
Race*
White
259 (76.2)
Black
27 (7.9)
Other
54 (15.9)
College degree†
64 (19.2)
Annual household income‡
Less than $30,000
56 (17.5)
$30,000 to $74,999
173 (54.1)
$75,000 or More
91 (28.4)
U.S. Census geographic region
Midwest
77 (22.6)
Northeast
31 (9.1)
South
191 (56.0)
West
42 (12.3)
Comorbidities
Congestive heart failure
55 (16.1)
Cardiac arrhythmia
74 (21.7)
Valvular disease
37 (10.9)
Pulmonary circulation disorder
9 (2.6)
Peripheral vascular disorder
51 (15.0)
Hypertension
228 (66.9)
Chronic pulmonary disease
73 (21.4)
Hypothyroidism
49 (14.4)
Renal failure
40 (11.7)
Liver disease
10 (2.9)
Obesity
15 (4.4)
Depression
33 (9.7)
Fluid and electrolyte disorder
49 (14.4)
Blood glucose testing strips
67 (19.7)
Number of medications
None
62 (18.2)
1 to 5
123 (36.1)
6 or more
156 (45.8)
Any diabetes medication
165 (48.4)
Sulfonylurea or meglitinide
63 (18.5)
Insulin
69 (20.2)
Antihypertensive medications
ACE inhibitor or ARB
111 (32.6)
Calcium channel blocker
31 (9.1)
Diuretic
77 (22.6)
Vasodilator
12 (3.5)
Other antiadrenergic
39 (11.4)
Statin
130 (38.1)
Beta-blocker post-MI
167 (49.0)
Data are means ± SD or N (%). All characteristics
are pre-MI except beta-blocker exposure. * Adds up
to 340 due to 1 missing value. † Adds up to 333 due
to 8 missing values. ‡ Adds up to 320 due to 21
missing values.
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Table 2 – Characteristics of new users and non-users of beta-blockers
New users of
beta-blockers
(N = 167)
61.1 ± 11.1

Non-users of
beta-blockers
(N = 174)
65.3 ± 14.5

Patient characteristics
P value
Age (years)
0.003 §
Sex
0.021
Male
108 (64.7)
91 (52.3)
Female
59 (35.3)
83 (47.7)
Race *
0.115
White
131 (78.9)
128 (73.6)
Black
8 (4.8)
19 (10.9)
Other
27 (16.3)
27 (15.5)
College degree †
33 (20.5)
31 (18.0)
0.567
Annual household income ‡
0.388
Less than $30,000
23 (14.8)
33 (20.0)
$30,000 to $74,999
84 (54.2)
89 (53.9)
$75,000 or More
48 (31.0)
43 (26.1)
U.S. Census geographic region
0.075
Midwest
37 (22.2)
40 (23.0)
Northeast
22 (13.2)
9 (5.2)
South
90 (53.9)
101 (58.1)
West
18 (10.8)
24 (13.8)
Comorbidities
Congestive heart failure
15 (9.0)
40 (23.0)
<0.001
Cardiac arrhythmia
23 (13.8)
51 (29.3)
0.001
Valvular disease
13 (7.8)
24 (13.8)
0.075
Pulmonary circulation disorder
6 (3.6)
3 (1.7)
0.328 ||
Peripheral vascular disorder
22 (13.2)
29 (16.7)
0.366
Hypertension
106 (63.5)
122 (70.1)
0.193
Chronic pulmonary disease
28 (16.8)
45 (25.9)
0.041
Hypothyroidism
19 (11.4)
30 (17.2)
0.123
Renal failure
11 (6.6)
29 (16.7)
0.004
Liver disease
6 (3.6)
4 (2.3)
0.535 ||
Obesity
7 (4.2)
8 (4.6)
0.855
Depression
11 (6.6)
22 (12.6)
0.059
Fluid and electrolyte disorder
13 (7.8)
36 (20.7)
0.001
Blood glucose testing strips
36 (21.6)
31 (17.8)
0.385
Number of medications
<0.001
None
19 (11.4)
43 (24.7)
1 to 5
76 (45.5)
47 (27.0)
6 or more
72 (43.1)
84 (48.3)
Any diabetes medication
89 (53.3)
76 (43.7)
0.076
Sulfonylurea or meglitinide
37 (22.2)
26 (14.9)
0.086
Insulin
35 (21.0)
34 (19.5)
0.745
Antihypertensive medications
ACE inhibitor or ARB
64 (38.3)
47 (27.0)
0.026
Calcium channel blocker
21 (12.6)
10 (5.8)
0.028
Diuretic
48 (28.7)
29 (16.7)
0.008
Vasodilator
5 (3.0)
7 (4.0)
0.606
Other antiadrenergic
20 (12.0)
19 (10.9)
0.759
Statin
69 (41.3)
61 (35.1)
0.234
Data are means ± SD or N (%). All characteristics are pre-MI except beta-blocker exposure. All P
values based on chi-square statistic except where denoted. * Adds up to 340 due to 1 missing value.
† Adds up to 333 due to 8 missing values. ‡ Adds up to 320 due to 21 missing values. § Two-sample
t-test statistic. || Fisher’s exact test statistic.
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Table 3 – Multivariable logistic regression model
predicting initiation of beta-blocker after myocardial
infarction among patients with type 2 diabetes
Patient characteristics
Adjusted OR (95% CI)
Age
0.98 (0.96–1.00)
Male
1.50 (0.91–2.47)
Black*
0.44 (0.16–1.19)
Congestive heart failure
0.45 (0.21–0.96)
Cardiac arrhythmia
0.44 (0.23–0.86)
Depression
0.50 (0.22–1.17)
Fluid and electrolyte disorder
0.48 (0.21–1.13)
Renal failure
No diuretic
0.17 (0.05–0.65)
Taking a diuretic
1.42 (0.35–5.86)
Number of medications
None
Referent
1 to 5
3.59 (1.74–7.38)
6 or more
1.46 (0.70–3.05)
Calcium channel blocker
2.63 (1.05–6.60)
All characteristics are pre-MI except beta-blocker exposure. All
variables from Table 2 were included in initial model except
college degree, pulmonary circulation disorder, liver disease,
and obesity. In the initial model, vasodilator and other
antiadrenergic were combined into other antihypertensive
category. For race, 1 patient with a missing value was placed in
the “Other” category. For annual household income, 21 patients
with missing values were placed in $30,000 to $74,999 category.
*Based on the results before inclusion of interactions terms, the
variable for race was changed to a variable indicating whether
the patient was black.
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